GSK profit misses as vaccine sales disappoint, stockpiling eases
Adds details on quarterly earnings
July 29 (Reuters) - Britain's GSK GSK.L fell short of quarterly expectations for profit on Wednesday, as sales of its existing vaccines fell and stockpiling of pain and lung medication tapered as countries eased coronavirus-induced lockdowns.
The company said it still expects adjusted earnings per share for the year to decline in the range of 1% to 4%, with the outcome dependent on the timing of a recovery in vaccination rates, particularly in the United States.
Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seven other global firms, including Sanofi SAY.PA and China's Clover.
GSK also signed a deal with Britain for up to 60 million doses of a possible COVID-19 vaccine being developed by the company and Sanofi SASY.PA. The company said discussions are underway with the EU and United States.
Vaccine sales fell 29% to £1.1 billion, below consensus of £1.26 billion. Sales of Shingrix, its blockbuster and recent growth driver, fell to £323 million, but was above estimates.
Turnoverfell 3% to 7.62 billion pounds in the three months ended June 30 on a constant currency basis, while adjusted earnings stood at 19.2 pence per share, the company said. GSK maintained its 2020 forecast.
Fourteen analysts on average expected second-quarter adjusted earnings of 20.1 pence per share and sales of 7.72 billion pounds, according to a company-compiled consensus.
PREVIEW-U.S. drugmaker earnings heat up this week with spotlight on vaccine news
GSK aims for 1 bln doses of booster as COVID-19 vaccine race heats up
GSK in quest to be best, not first, in race for COVID-19 vaccine
GSK begins U.S. test of experimental drug for pneumonia from COVID-19
GSK to test experimental drug to treat pneumonia from COVID-19
FACTBOX-Worldwide coronavirus cases
FACTBOX-The race for a coronavirus vaccine
FACTBOX-Drugmakers rush to develop COVID-19 treatments
GRAPHIC-Tracking and explaining the new coronavirushttps://tmsnrt.rs/2GVwIyw
(Reporting by Pushkala Aripaka, Ankur Banerjee in Bengaluru; and Ludwig Burger in Frankfurt; Editing by Bernard Orr)
((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; within UK: +44 20 7542 1810, outside UK: +91 80 6182 2600; Mobile: +91 852 751 3793;))